Aidoc Raises $150M Series E Led by Goldman Sachs to Scale Clinical AI for Faster, Safer Diagnoses
Aidoc, an Israeli-founded clinical AI company, has secured $150 million in a Series E funding round.
The round was led by Goldman Sachs Growth Equity, with participation from General Catalyst, SoftBank Investment Advisors, and NVentures, the venture arm of NVIDIA.
Company Background and Innovation
Aidoc specializes in AI-powered medical imaging solutions that detect critical conditions in CT scans, X-rays, and other diagnostics.
Founded in Israel and now headquartered in New York, the startup has pioneered the aiOS enterprise platform and the CARE Clinical AI Reasoning Engine.
Prior to this, Aidoc raised another $150 million in 2025, bringing its total funding to over $500 million.
Transformative Impact on Healthcare
The technology addresses diagnostic errors, which contribute to hundreds of thousands of deaths annually in the US alone.
By prioritizing urgent cases, Aidoc's tools enable radiologists to act faster, improving patient outcomes and reducing hospital burdens.
Future Expansion and Vision
Funds will accelerate CARE development, expand into new clinical areas, and introduce features like automated imaging report drafts.
The investment supports global deployment of aiOS across hospitals, aiming for broader AI integration in workflows.
With partnerships including NVIDIA and major health systems, Aidoc positions itself at the forefront of clinical AI advancement.
This raise underscores investor confidence in AI's role in revolutionizing diagnostics amid growing healthcare demands.
